238 related articles for article (PubMed ID: 37175439)
1. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract][Full Text] [Related]
2. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells.
Carmi YK; Agbarya A; Khamaisi H; Farah R; Shechtman Y; Korobochka R; Gopas J; Mahajna J
Transl Oncol; 2024 Jun; 44():101939. PubMed ID: 38489872
[TBL] [Abstract][Full Text] [Related]
4. 2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.
Khamaisi H; Mahmoud H; Mahajna J
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164068
[TBL] [Abstract][Full Text] [Related]
5. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migration and Platinum Resistance by Rescuing Hedgehog-Mediated Autophagy.
Ferraresi A; Esposito A; Girone C; Vallino L; Salwa A; Ghezzi I; Thongchot S; Vidoni C; Dhanasekaran DN; Isidoro C
Cells; 2021 Nov; 10(11):. PubMed ID: 34831435
[No Abstract] [Full Text] [Related]
7. Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness.
Huang Z; Byrd O; Tan S; Hu K; Knight B; Lo G; Taylor L; Wu Y; Berchuck A; Murphy SK
Sci Rep; 2023 Dec; 13(1):21382. PubMed ID: 38049490
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
[TBL] [Abstract][Full Text] [Related]
9. In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.
Berkel C; Cacan E
Cell Biol Int; 2020 Aug; 44(8):1598-1605. PubMed ID: 32208526
[TBL] [Abstract][Full Text] [Related]
10. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
11. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation.
Castells M; Milhas D; Gandy C; Thibault B; Rafii A; Delord JP; Couderc B
Cell Death Dis; 2013 Oct; 4(10):e887. PubMed ID: 24176845
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review).
Zhang Q; Ding J; Wang Y; He L; Xue F
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35362546
[TBL] [Abstract][Full Text] [Related]
14. [Epithelial ovarian cancer].
Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
[TBL] [Abstract][Full Text] [Related]
15. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.
Wang Y; Zong X; Mitra S; Mitra AK; Matei D; Nephew KP
JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518684
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells.
Jang YS; Kim TW; Ryu JS; Kong HJ; Jang SH; Nam GH; Kim JH; Jeon S
PLoS One; 2023; 18(2):e0277285. PubMed ID: 36757936
[TBL] [Abstract][Full Text] [Related]
18. CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment.
Yang YI; Wang YY; Ahn JH; Kim BH; Choi JH
Biomed Pharmacother; 2022 Sep; 153():113474. PubMed ID: 36076499
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
Qian J; LeSavage BL; Hubka KM; Ma C; Natarajan S; Eggold JT; Xiao Y; Fuh KC; Krishnan V; Enejder A; Heilshorn SC; Dorigo O; Rankin EB
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396988
[TBL] [Abstract][Full Text] [Related]
20. Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
Ray U; Roy D; Jin L; Thirusangu P; Staub J; Xiao Y; Kalogera E; Wahner Hendrickson AE; Cullen GD; Goergen K; Oberg AL; Shridhar V
J Exp Clin Cancer Res; 2021 Jun; 40(1):182. PubMed ID: 34082797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]